IMNN

Business Context and Reporting Period

This Form 10-Q covers Celsion Corporation for the quarterly period ended March 31, 2004. Celsion is a medical technology company developing focused-heat therapies for cancer and other diseases. The company recently received FDA premarketing approval (PMA) on February 19, 2004, for its Prolieve Thermodilatation system to treat Benign Prostatic Hyperplasia (BPH), marking the beginning of commercialization through a distribution agreement with Boston Scientific Corporation. The company changed its fiscal year-end from September 30 to December 31 effective December 31, 2003.

Key Financial Metrics

Liquidity and Debt: The company reported no long-term debt. Current liabilities totaled $3,175,864, primarily driven by accounts payable ($1,997,017) and deferred revenue ($571,428). The company holds a $2,000,000 escrow account related to the Boston Scientific licensing fee.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded its first commercial sales of $100,000 in Q1 2004, compared to zero in Q1 2003, following the FDA approval of the Prolieve system.
• Operating Loss Increase: Net loss increased by approximately 28% to $6.07 million. This was driven by a 28% increase in total operating expenses to $6.16 million.
• Expense Drivers:
  • General & Administrative: Increased by $428,367 (38%), largely due to a $410,000 investment banking fee paid to Legg Mason.
  • R&D: Increased by $933,524 (26%), primarily due to a separation agreement with a former executive and costs related to clinical trials.
• Cash Position: Cash increased by $7.15 million to $19.4 million, fueled by $10.03 million in financing activities (stock issuances and warrant exercises) and $4.0 million in licensing fees received from Boston Scientific.

Guidance, Outlook, and Risks

Outlook and Guidance: Management anticipates that available cash will fund operations through December 2005. The company expects to expend approximately $12 million in fiscal year 2004 on clinical testing for breast cancer, prostate cancer, and liver cancer treatments, as well as corporate overhead. Future revenue is expected to come from the Prolieve system and catheter kits, though timing and volume are uncertain.

Unusual Items: Q1 2004 expenses included approximately $2.26 million in nonrecurring items:

• $350,000 termination fee for migrating catheter manufacturing.
• $410,000 investment banking fee.
• $972,000 separation costs for a former executive.
• $623,000 in cash bonuses tied to FDA approval.

Risks and Contingencies:

• Funding: The company has no committed sources of financing beyond current cash and may need to raise additional capital, potentially through dilutive equity offerings.
• Commercialization: Success depends heavily on Boston Scientific's ability to market the Prolieve system effectively.
• Regulatory: Other pipeline products (breast cancer, ThermoDox, CRI) remain in clinical or pre-clinical stages and require FDA approval.
• Supplier Dependence: The company relies on third-party suppliers for manufacturing and components.

Investor Verification Checklist

• Revenue Sustainability: Verify if the $100,000 in sales represents a one-time shipment or the start of recurring revenue from the Prolieve system.
• Boston Scientific Performance: Monitor sales data and market adoption of the Prolieve system by the distributor.
• Cash Burn Rate: Confirm the $12 million projected spend for fiscal 2004 against actual quarterly cash usage to validate the "funded through Dec 2005" claim.
• Escrow Terms: Review the specific contingencies attached to the $2,000,000 escrow account held for the Boston Scientific license fee.
• Clinical Trial Progress: Track the status of Phase II breast cancer trials and Phase I ThermoDox trials, as these are critical for future valuation.